Prognostic and Predictive Immunohistochemistry-Based Biomarkers in Cancer and Immunotherapy - 03/03/19

Doi : 10.1016/j.hoc.2018.12.005

Emanuelle M. Rizk, BA ^a, Robyn D. Gartrell, MD ^a, Luke W. Barker, BS ^b, Camden L. Esancy, MS ^a, Grace G. Finkel, BA ^b, Darius D. Bordbar, BS ^b, Yvonne M. Saenger, MD ^a,^⁎
^a Department of Medicine, Columbia University Irving Medical Center, 650 West 168th Street, Black Building 8-816, New York, NY 10032, USA
^b College of Physicians and Surgeons, Columbia University Irving Medical Center, 650 West 168th Street, Black Building 8-816, New York, NY 10032, USA

^∗Corresponding author.

Resumen

Immunotherapy has drastically improved the prognosis of many patients with cancer, but it can also lead to severe immune-related adverse events. Biomarkers, which are molecular markers that indicate a patient’s disease outcome or a patient’s response to treatment, are therefore crucial to helping clinicians weigh the potential benefits of immunotherapy against its potential toxicities. Immunohistochemistry (IHC) has thus far been a powerful technique for discovery and use of biomarkers such as CD8⁺ tumor-infiltrating lymphocytes. However, IHC has limited reproducibility. Thus, if more IHC-based biomarkers are to reach the clinic, refinement of the technique using multiplexing or automation is key.

El texto completo de este artículo está disponible en PDF.

Keywords : Immunotherapy, Predictive and prognostic biomarkers, Checkpoint inhibition, Immunohistochemistry